REGN — Regeneron Pharmaceuticals Inc. stock price and chart

REGN

Regeneron Pharmaceuticals Inc.Stock · HealthcareNasdaq-100 0.3% · S&P 500 Equal Weight 0.2% · Nasdaq Composite 0.1% · S&P 500 0.10% · Russell 1000 0.09% · US Stock Market 0.09% · Russell 3000 0.09% · MSCI ACWI 0.07% · MSCI World 0.07%

$781.49-1.48%

as of market close, Sep 11, 2026

☾ AH — —

PeersMRNALLYUNHJNJMRKABBV

Technical analysis2

Overlay lines0

Addendum charts0

VolumeDDDDDDD

20162019202120242026

300.0400.0500.0600.0700.0800.0900.01000.01100.0010.0M20.0M$781.49

2026-09-11

Price$781.49

MA20$715.93

MA50$688.97

Vol3.2M

What would $1,000 invested in REGN be worth today? →

REGN returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $781.49
Change YTD: +1.64%
Next earnings: Oct 27, 2026
Market cap: 80.5B2016-09 46.8B2026-09 80.4B+71.8% over the window
Enterprise value: 75.4B
Shares outstanding: 103M2016-06 116.2M2026-06 103M-11.4% over the window
52W low: $541.00
52W high: $859.34
From 52W high: -9.06%
From 52W low: +44.45%
52W range: 76%
Beta: 0.20

Volume

Rel volume: 0.64×
30D volume: 694.6K
30D $ vol: 558.1M

Fundamentals

Sales (ttm): 15.5B2016-06 4.6B2026-06 15.5B+234.2% over the window
Sales/share: $150.892016-06 $40.002026-06 $150.89+277.2% over the window
EPS (ttm): $40.402016-06 $6.442026-06 $40.40+527.3% over the window
FCF (ttm): 3.8B2016-06 1.1B2026-06 3.8B+257.3% over the window
FCF/share: $36.522016-06 $9.052026-06 $36.52+303.4% over the window
Book value/share: $308.012016-06 $35.072026-06 $308.01+778.2% over the window
Net margin: 27.86%2016-06 16.0%2026-06 27.9%+74.4% over the window
ROE: 13.65%2016-06 18.2%2026-06 13.7%-25.1% over the window
ROA: 10.37%2016-06 12.0%2026-06 10.4%-13.4% over the window
Debt / equity: 0.06×2019-12 0.002026-06 0.06
Current ratio: 3.342016-06 3.372026-06 3.34-1.1% over the window

Growth (CAGR, ttm) · 10Y

Sales: +9.30%2025-06-30 → 2026-06-3014.2B → 15.5B (+9.3% total)+7.03%2023-06-30 → 2026-06-3012.7B → 15.5B (+22.6% total)+4.64%2021-06-30 → 2026-06-3012.4B → 15.5B (+25.4% total)+12.82%2016-06-30 → 2026-06-304.6B → 15.5B (+234.2% total)
Net income: -2.92%2025-06-30 → 2026-06-304.5B → 4.3B (-2.9% total)+0.23%2023-06-30 → 2026-06-304.3B → 4.3B (+0.7% total)-6.95%2021-06-30 → 2026-06-306.2B → 4.3B (-30.2% total)+19.27%2016-06-30 → 2026-06-30743M → 4.3B (+482.6% total)
FCF: -2.42%2025-06-30 → 2026-06-303.9B → 3.8B (-2.4% total)-3.25%2023-06-30 → 2026-06-304.2B → 3.8B (-9.5% total)+17.30%2021-06-30 → 2026-06-301.7B → 3.8B (+122.0% total)+13.58%2016-06-30 → 2026-06-301.1B → 3.8B (+257.3% total)
Shares: -2.86%2025-06-30 → 2026-06-30106M → 103M (-2.9% total)-1.75%2023-06-30 → 2026-06-30108.6M → 103M (-5.2% total)-0.76%2021-06-30 → 2026-06-30107M → 103M (-3.7% total)-1.21%2016-06-30 → 2026-06-30116.2M → 103M (-11.4% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +1.84%2025-06-30 → 2026-06-30$39.67 → $40.40 (+1.8% total)+2.23%2023-06-30 → 2026-06-30$37.81 → $40.40 (+6.8% total)-6.22%2021-06-30 → 2026-06-30$55.69 → $40.40 (-27.5% total)+20.16%2016-06-30 → 2026-06-30$6.44 → $40.40 (+527.3% total)
Sales/share: +12.52%2025-06-30 → 2026-06-30$134.11 → $150.89 (+12.5% total)+8.93%2023-06-30 → 2026-06-30$116.72 → $150.89 (+29.3% total)+5.44%2021-06-30 → 2026-06-30$115.79 → $150.89 (+30.3% total)+14.20%2016-06-30 → 2026-06-30$40.00 → $150.89 (+277.2% total)
FCF/share: +0.45%2025-06-30 → 2026-06-30$36.36 → $36.52 (+0.5% total)-1.53%2023-06-30 → 2026-06-30$38.25 → $36.52 (-4.5% total)+18.20%2021-06-30 → 2026-06-30$15.83 → $36.52 (+130.7% total)+14.97%2016-06-30 → 2026-06-30$9.05 → $36.52 (+303.4% total)
Book value/share: +9.05%2025-06-30 → 2026-06-30$282.48 → $308.01 (+9.0% total)+11.66%2023-06-30 → 2026-06-30$221.24 → $308.01 (+39.2% total)+16.85%2021-06-30 → 2026-06-30$141.44 → $308.01 (+117.8% total)+24.27%2016-06-30 → 2026-06-30$35.07 → $308.01 (+778.2% total)
Dividend/share: +119.61%2025-06-30 → 2026-06-30$1.66 → $3.64 (+119.5% total)n/an/an/a
Price: +37.57%2025-09-11 → 2026-09-11$568.20 → $781.49 (+37.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-2.13%2023-09-11 → 2026-09-11$833.53 → $781.49 (-6.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+3.74%2021-09-10 → 2026-09-11$650.49 → $781.49 (+20.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+7.35%2016-09-09 → 2026-09-11$384.43 → $781.49 (+103.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +38.27%2025-09-11 → 2026-09-11$565.30 → $781.49 (+38.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-1.82%2023-09-11 → 2026-09-11$825.74 → $781.49 (-5.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+3.93%2021-09-10 → 2026-09-11$644.41 → $781.49 (+21.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+7.45%2016-09-09 → 2026-09-11$380.84 → $781.49 (+105.2% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 19.3×2016-09 58.722026-09 18.58-68.4% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 20.9×2016-09 38.542026-09 20.93-45.7% over the window
Fwd P/E: 13.4×
P/S (ttm)Market cap ÷ TTM revenue.: 5.2×2016-09 9.902026-09 5.18-47.7% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 2.5×2016-09 10.432026-09 2.54-75.7% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 21.4×2016-09 55.872026-09 21.39-61.7% over the window
EV/EBITDA (fy): 17.3×
EV/Sales (ttm): 4.9×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 4.67%2016-06 2.2%2026-06 5.8%+158.6% over the window
Dividend yield (fwd)Indicated forward annual dividend ÷ current price — the rate the company has announced, not what was actually paid over the past year.: 0.47%
Dividend/share (fwd): $3.64
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 103.0M ÷ 106.0M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 2.86%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (2.86%) + dividends paid over that year ($378.5M) ÷ market_cap_at(2025-06-30) ($57B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 3.53%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($2.5B) ÷ today's market cap ($80.5B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 3.16%2016-06 -0.3%2026-06 3.9%-1293.9% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $2.5B + TTM dividends $378.5M) ÷ today's market cap ($80.5B). Same caveat as the cash buyback yield.: 3.63%2016-06 -0.3%2026-06 4.5%-1471.6% over the window

Vs own 10Y history

P/E: 44th
P/OI: 60th
P/S: 19th
P/B: 11th
P/FCF: 40th

Bar = where today’s multiple sits in REGN’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · windows as of 2026-09-11

-1.48%

-7.35%

-1.95%

+27.95%

YTD

+1.64%

+41.32%

+16.74%

Financial statements

Open full REGN financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	-8.44%	-0.65%
JNJ	Johnson & Johnson	+2.31%	-0.29%
ABBV	AbbVie Inc.	+3.36%	+0.83%
MRK	Merck & Co. Inc.	+8.28%	-0.54%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	-6.53%	-2.37%
TMO	Thermo Fisher Scientific Inc.	+1.13%	+1.10%
AMGN	Amgen Inc.	-8.80%	-1.34%
GILD	Gilead Sciences Inc.	+5.78%	-0.75%

Regeneron Pharmaceuticals Inc. (REGN) trades at $781.49 with a live price and an interactive chart covering 35+ years of daily price history, plus key valuation metrics. ChartRow also publishes REGN’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full REGN financial statements →

REGN — Regeneron Pharmaceuticals Inc. price, chart and key statistics